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A unique clinical syndrome has been described in
which patients have chronic oral ulceration and
autoantibodies to nuclei of stratified squamous epi-
thelium. We have characterized the autoantibodies
from patient sera and found that the major autoantigen
is a 70 kDa epithelial nuclear protein. Sequencing of
the cDNA for this protein, chronic ulcerative stomatitis
protein, revealed it to be homologous to the p53 tumor
In 1990, Jaremko and coworkers reported a unique clinicalsyndrome in which patients had chronic ulcerative stomatitis(hereafter referred to as CUS) and IgG antibodies to keratino-cyte nuclei (Jaremko et al, 1990). The antibodies were presentin the circulation, the skin, and the oral mucosa of affected
individuals. As the circulating autoantibodies bound a nuclear antigen
that was present in epidermis and in esophageal epithelium but was
undetectable in kidney or in HEp-2 cells, it was speculated that the
expression of the autoantigen was limited to stratified squamous
epithelium. Parodi and Cardo (1990), reporting two cases similar to
those of Jaremko and coworkers, identified an epithelial autoantigen
migrating in the range of 70–75 kDa. Antigenicity was adversely
affected by DNAses, indicating that the antigen may bind DNA. In
this report, using sera from patients with autoantibody-associated
CUS, we characterize CUSP (chronic ulcerative stomatitis protein),
a 70 kDa protein bound by the autoantibodies. Sequencing of the
cDNA for CUSP reveals it to be homologous to the p53 tumor
suppressor and to the p73 putative tumor suppressor, and to be a
splicing variant of the newly described p53-like gene, KET.
MATERIALS AND METHODS
Sera Serum samples were obtained from nine patients seen at the Warsaw
School of Medicine who had CUS and a particulate pattern of IgG
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suppressor and to the p73 putative tumor suppressor,
and to be a splicing variant of the KET gene. The p53-
like genes, p73 and the several KET splicing variants,
are recently described genes of uncertain biologic and
pathologic significance. This study provides the first
clear association of a p53-like protein with a disease
process. Key words: KET/p73/tumor suppressor. J Invest
Dermatol 113:146–151, 1999
deposition in keratinocyte nuclei in direct and indirect immunofluorescence
studies. Control samples were from 10 healthy volunteers and from patients
with one of the following diseases: recurrent aphthous stomatitis (24
subjects), oral lichen planus (six subjects), autoantibody-positive dermato-
myositis (two subjects), and autoantibody-positive lupus erythematosus. Of
the autoantibody-positive subjects with lupus, 15 had discoid skin lesions,
15 had subacute cutaneous skin lesions, and two had systemic disease with
no skin lesions. Of the patients with discoid lesions, five had systemic disease.
Of the patients with subacute cutaneous lesions, six had systemic disease.
Cell culture Normal human neonatal foreskin keratinocytes were cul-
tured in keratinocyte serum-free medium purchased from GibcoBRL
(Gaithersburg, MD). Contaminating melanocytes were removed by a 5 min
incubation with 0.025% trypsin 1 0.02% ethylenediamine tetraacetic acid
and recultured. HeLa cells (cervical carcinoma), A431 cells (epidermoid
carcinoma), and COS-1 cells (monkey kidney cells) were obtained from
American Type Culture Collection (Manassas, VA), HaCaT cells (trans-
formed keratinocytes) were obtained originally from Professor Norbert
Fusenig (German Cancer Research Center, Heidelberg, Germany), and
human WM1617 melanoma cells were obtained from the Wistar Institute
(Philadelphia, PA). Unless stated otherwise, cultures were used for experi-
ments at µ80% confluence.
Immunofluorescence Cultured keratinocytes, melanocytes, A431,
HaCaT, HeLa, COS, and WM1617 melanoma cells were plated on to
eight-well LabTek slides (Nalgene, Naperville, IL) for microscopy studies.
Cells were permeabilized with cold acetone for 1 min prior to incubation
with sera. HEp-2 cells on microscope slides were purchased ready for use
from INOVA (San Diego, CA). Sera were diluted 1:100, 1:1000, and
1:10,000 in phosphate-buffered saline and overlaid on the slides for 1 h at
room temperature. Antibody binding was identified using a 1:250 dilution
of fluorescein-conjugated anti-human IgG purchased from Dako (Carpen-
teria, CA).
Immunoblotting and immunoprecipitation Protein extracts were
prepared from cultured normal human neonatal keratinocytes and from
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HeLa cells, and from epidermal sheets obtained immediately after trypsin
separation of epidermis from dermis. Extracts were subjected to standard
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, then proteins
were transferred on to nitrocellulose paper and immunoblotted with
1:100 dilutions of CUS sera and control sera (Targoff et al, 1993).
Immunoprecipitation of 35S-labeled keratinocytes and HeLa cells and RNA
immunoprecipitation were performed according to previously published
techniques (Targoff et al, 1993).
Keratinocyte cDNA library preparation A keratinocyte cDNA library
was prepared from a culture of normal human neonatal keratinocytes using
a ZAP Express cDNA Synthesis Kit from Stratagene (La Jolla, CA)
according to the manufacturer’s instructions. The library was packaged
using the Gigapack II Gold packaging extract from Stratagene and plated
on the Escherichia coli cell line XL1-Blue MRF9.
Cloning and sequencing CUS sera were used at a 1:1000 dilution to
screen the human keratinocyte cDNA library. Candidate clones were
subcloned and tested for reactivity with other CUS sera and with control
sera. Sequencing was performed by the University of Colorado Cancer
Center DNA Sequencing and Analysis Core Facility.
Sequencing of the cDNA 59 of the cloned cDNA was accomplished
using a 59 Rapid Amplication of cDNA Ends (RACE) technique (Kozak,
1987). Epidermal sheets were separated from the dermis by overnight
incubation in 0.5 M ammonium thiocyanate in 0.1 M sodium phosphate
buffer, pH 6.8. The epidermal sheets were suspended in TRIzol reagent (a
monophasic solution of phenol and guanidine isothiocyanate, GibcoBRL),
subjected to several freeze/thaw cycles, and processed according to the
manufacturer’s specifications. First-strand cDNA synthesis used the Super-
Script II RNase H– Reverse Transcriptase (GibcoBRL) with gene-specific
primers. After cDNA synthesis, the RNA template was degraded using a
mixture of RNase H and RNase T1 and the RNA-free cDNA was then
used as a template for the RACE technique. A homopolymeric tail was
added to the 39 end of the cDNA (corresponding to the 59 end of the
mRNA) using TdT and dCTP. Polymerase chain reaction amplification
was accomplished using Taq DNA polymerase, a nested, gene-specific
primer that annealed to a site located within the cDNA molecule, and a
deoxyinosine-containing anchor primer.
The deduced amino acid sequences and the sequence comparisons were
performed using the GenBank database and the BLAST 2.0.4 program
(Altschul et al, 1997). Sequence alignment was performed using the
ClustalW Multiple Sequence Alignment program obtained from Kim
Worley of the Human Genome Center, Baylor College of Medicine,
Houston, TX.
Transfection of COS cells Full-length CUSP was expressed in COS
cells, which do not normally express CUSP, using cationic liposome-
mediated transfection. The transfection procedure utilized the FuGENE 6
Transfection Reagent (Roche Molecular Biochemicals; Basel, Switzerland)
according to the manufacturer’s directions. Expression of CUSP was
examined using CUS patient sera and affinity-purified anti-CUSP in an
immunofluorescence technique.
Affinity purification of anti-CUSP Antibodies to the protein expressed
by the clone (a partial sequence consisting of the 39 end of CUSP) were
affinity purified by the following technique. A nitrocellulose filter of
µ50 cm2 was overlaid on E. coli colonies containing the clone. Patient
serum diluted 1:100 was incubated with the nitrocellulose for 2 h. Following
washing, antibodies bound to the nitrocellulose were eluted for 10 min
with 1 ml of 100 mM glycine, pH 2.5, then 30 µl of 1 M Tris,
pH 9, was added. These affinity-purified antibodies were then used in
immunoblotting. Control antibodies were obtained by affinity purification
against E. coli containing vector without insert.
Antibodies to the full-length CUSP protein were prepared using a
Sepharose 4B column (Pharmacia, Piscataway, NJ) containing the protein
product of full-length CUSP cDNA. Antibodies were eluted with glycine
as above, and then dialyzed against phosphate-buffered saline prior to use
in immunoblotting or immunofluorescence.
Immunization of rabbits Two adult New Zealand white rabbits were
immunized with a peptide containing amino acids 4–17 from the N9-
terminus of CUSP, using a standard immunization protocol with the KLH-
conjugated CUSP peptide diluted in the adjuvant TiterMax Classic (Sigma,
St. Louis, MO). Boosting was performed every 3 wk. Antibody responses
were assessed preimmunization, at 3 wk, and at 6 wk, using immunofluo-
rescence and immunoblotting.
Figure 1. Cellular location of autoantibodies in chronic ulcerative
stomatitis. Cultured normal human keratinocytes were incubated with
serum from a patient with chronic ulcerative stomatitis. Antibody binding
is identified using a fluoresceinated probe. There is particulate staining of
keratinocyte nuclei. Scale bar: 10 µm.
Northern blot analysis The expression of CUSP mRNA was examined
using a standard northern blotting technique. Total RNA was extracted
from cultured human keratinocytes, human melanoma cells, COS cells,
A431 cells, and HaCaT keratinocytes. Following electrophoresis, the RNA
was probed with a digoxygenin-labeled probe derived from the 59 sequence
of CUSP. The probe consisted of 630 bp extending from 60 bp into the
59 UTR through bp 570 in the coding region.
RESULTS
Antibodies in CUS sera bind keratinocyte nuclei in immuno-
fluorescence IgG antibodies in CUS sera bound nuclei of normal
human keratinocytes, A431 cells, and HaCaT cells with a particulate
pattern (Fig 1). Nuclear staining was absent when HEp-2, HeLa,
COS cells, normal human melanocytes, and WM1617 melanoma
cells were used. Normal human keratinocyte cultures were
examined at µ50%, 80%, and 100% confluence, and at each of
these conditions strong nuclear staining was observed.
Antibodies in CUS sera identify a 70 kDa keratinocyte
protein Each of the CUS sera contained antibodies to a protein
migrating at µ70 kDa in immunoblotting (Fig 2A). The protein
was present in keratinocytes and epidermal sheets but absent in
HeLa cells. Although other antibody specificities were present in
the sera, the specificity common to all the sera was anti-70 kDa.
Six of nine sera also contained antibodies to a protein of µ52 kDa
present in keratinocytes but not detected in HeLa cells.
In the evaluation of the control sera, all samples from normal
individuals and all samples from patients with autoimmune diseases
(dermatomyositis and lupus erythematosus) were tested in both
immunofluorescence and immunoblotting. The samples from
patients with recurrent aphthous stomatitis and oral lichen planus
were first screened with immunofluorescence, and those showing
nuclear staining (two samples) were then tested in immunoblotting
to determine whether the autoantibodies were specific for CUSP.
Antibodies to CUSP were not detected in control sera from these
74 controls consisting of 10 healthy subjects, 24 patients with
recurrent aphthous stomatitis, six patients with oral lichen planus,
two patients with dermatomyositis, 15 patients with subacute
cutaneous lupus, 15 patients with discoid lupus, and two patients
with systemic lupus erythematosus without cutaneous lesions.
Similar results were obtained with protein immunoprecipitation
performed with five of the CUS sera and five control sera (Fig 2B).
A 70 kDa protein was precipitated from keratinocyte but not HeLa
cell extract. The 70 kDa protein was the only protein precipitated
by all CUS sera and no control sera, and detected in keratinocytes
but not HeLa cells. The precipitates were also examined for RNA
complexed with the autoantigen. No RNAs were present in the
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Figure 2. CUS antibodies bind a 70 kD
keratinocyte protein. (a) Immunoblot with HeLa cell
extract (left side) and cultured keratinocyte extract (right
side). Reactivity of cell extracts with control normal
sera is shown in lanes 1 and 2. Reactivity with control
dermatomyositis and lupus sera is shown in lanes 3–5.
Reactivity with CUS sera is shown in lanes 6–10. A
different serum is used for each lane. The CUS sera
bind a protein migrating at 70 kDa (arrow) present in
the keratinocyte extract but not the HeLa cell extract.
(b) Immunoprecipitation of proteins from HeLa cells
(left side) and cultured keratinocytes (right side). Proteins
precipitated by normal sera are shown in lanes 1 and 2,
and proteins precipitated by dermatomyositis and lupus
sera are shown in lanes 3–5. Proteins precipitated by
CUS sera are shown in lanes 6–10. The notable finding
is the presence of a protein at 70 kDa precipitated from
keratinocytes but not HeLa cells by CUS antibodies.
precipitates using the CUS sera, indicating that the CUS-associated
autoantigen is not a ribonucleoprotein (data not shown).
Sequencing of the 70 kDa antigen, CUSP A keratinocyte
cDNA expression library was screened using CUS sera. A candidate
clone was identified which bound six of six CUS and none of five
normal sera. Antibodies affinity purified to the clone reacted with
a single band of 70 kDa in immunoblotting. The cDNA consisted
of µ3500 nucleotides. Approximately 700 nucleotides were in the
coding region, and the remaining 2800 nucleotides were in a large
39 UTR. In order to obtain the 1100 nucleotides that were in the
coding region for CUSP but were 59 of the clone, 59 RACE
was used.
Once the full coding sequence of CUSP was obtained, a
full-length CUSP insert was used to affinity purify anti-CUSP
antibodies. The affinity-purified antibodies produced nuclear stain-
ing of cultured keratinocytes in immunofluorescence. Affinity
purification to the full-length CUSP protein produced a 70 kDa
band in immunoblotting and nuclear staining of keratinocytes in
immunofluorescence.
As further evidence confirming that the sequence represents
CUSP, the cDNA sequence was used for polycationic transfection
of COS cells. COS cells do not normally express CUSP, as was
verified by immunofluorescence, immunoblotting, and northern
blotting. Following transfection of COS cells with the cDNA,
there was nuclear expression of the protein (Fig 3).
Finally, rabbits immunized to a peptide of CUSP developed
antibodies to a 70 kDa keratinocyte protein and their sera produced
staining of keratinocyte nuclei in immunofluorescence.
Homology of CUSP to p53 and p53-like genes The predicted
amino acid sequence of CUSP is homologous to rat KET, p73 and
p53 (Fig 4). In humans, several genes have been reported recently
which are human homologs of rat KET, including p51, p40, and
p73L. Their predicted amino acid sequences are shown in Fig 4,
with the exception of p73L, which differs from CUSP only at
three amino acid positions, and rat KET, which is nearly identical
to human p51B. CUSP and p40 are virtually identical at the 59
end, but CUSP contains an additional 230 amino acids at the
C-terminus. Two variants of p51, p51A (predicted to be 51 kDa)
and p51B (predicted to be 72 kDa) have been described (Osada
et al, 1998). CUSP is identical to the p51B variant except for the
59-most amino acids. An overview of the KET variants is presented
in Fig 5. There are at least three splicing variants of KET: CUSP/
p73L, p51B, and p51A. It is not clear whether p40 is a distinct
splice variant or an incompletely sequenced gene. Two variants of
p73, α and β, have been reported, with p73β being a splicing
variant lacking exon 13 (Kaghad et al, 1997). CUSP more closely
resembles the p73α variant, having an µ60% identity to p73α in
its predicted amino acid sequence.
A comparison of the KET variants to p73 and human p53 in
the four conserved regions (II–V) of the DNA-binding domain
can be seen from examination of Fig 4. In these regions, the
Figure 3. Expression of CUSP protein in COS cells. Following
polycationic transfection of full-length CUSP, CUSP expression was
identified using CUS serum and an immunofluorescence technique. The
transfected COS cells show nuclear fluorescence. Scale bar: 10 µm.
sequences of CUSP and all the other KET variants are identical.
The amino acid identities between KET and p73 and human p53,
respectively, are as follows: 92% and 65% for region II; 90% and
90% for region III; 96% and 81% for region IV; and 94% and 71%
for region V. Thus, the KET gene is more closely related to p73
than to p53.
Expression of CUSP mRNA Northern blotting of cultured
keratinocytes revealed a strong band of µ4.7 kb, and a weak band
of µ5.8 kb (Fig 6). No bands were detected in COS cells or
human melanoma cells. The CUSP 4.7 kb transcript was readily
detected in A431 cells and HaCaT cells, but the 5.8 kb transcript
was not detected in either of those cell lines.
DISCUSSION
The syndrome of chronic ulcerative stomatitis with antibodies to
a nuclear antigen of stratified epithelium is defined both by
its clinical phenotype and its autoantibody specificity. CUS is
characterized clinically by erosive and exfoliative oral lesions, a
chronic course with exacerbations and remissions, predominance
of females and older individuals, and a therapeutic response to
chloroquine (Chorzelski et al, 1998). Circulating and tissue-bound
IgG antibodies to a keratinocyte nuclear antigen are required for
diagnosis (Jaremko et al, 1990; Beutner et al, 1991). We have
characterized the CUSP autoantigen and shown it to be homologous
to p53 and p73, and to be a variant of the p53-like KET gene.
The p53 tumor suppressor plays a crucial part in the prevention
of tumorigenesis, allowing cells that are damaged to repair that
damage before cell division takes place and directing cells that are
overwhelmingly damaged to commit suicide through apoptosis
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Figure 4. Predicted amino acid sequence of
CUSP and its comparison with p51A, p51B,
p73a, p73b, and human p53. The cDNA sequence
of CUSP is available through GenBank, accession
number AF091627. The predicted amino acid
sequences of p51A, p51B, p73α, p73β, and p53 were
transcribed directly from GenBank. The sequence
alignment was performed by the ClustalW Multiple
Sequence Alignment program. The boxed areas
represent the transactivation (I) domain, the conserved
regions (II–V) of the sequence-specific DNA binding
domain, and the oligomerization (OLIG) domain.
(Chang et al, 1995; Nataraj et al, 1995; Brash and Bale, 1997).
Recently, p53-like genes have been discovered, either fortuitously
or through a directed search using degenerate primers from highly
conserved regions of p53. We have found a p53-like gene through
a different pathway, as a result of characterizing the autoantigen of
a unique clinical syndrome in which patients have CUS and IgG
antibodies to keratinocyte nuclei (Jaremko et al, 1990). The
autoantigen, which we termed ‘‘CUSP’’, for chronic ulcerative
stomatitis protein, is homologous to rat KET. The p53-like rat
KET gene was identified fortuitously in rat tongue papillae and
shown to be restricted in its expression to oral epithelium, skin,
and thymus (Schmale and Bamberger, 1997). During the course of
this work, several human homologs of KET have been reported
as a result of a search for p53-like genes. These include: p40, which
contains the 59 sequence of CUSP (Trink et al, 1998); p73L,
which is almost identical to CUSP (Senoo et al, 1998); and p51B,
which contains the 39 sequence of CUSP (Osada et al, 1998). In
general, unlike p53 itself, the p53-like proteins are not expressed
in all tissues, but rather are restricted in their tissue expression
(Kaelin, 1998). Although these genes are clearly homologous to
p53, their role as tumor suppressors is uncertain (Kaelin, 1998).
The 59 identity of CUSP to p40 and the 39 identity of CUSP
to p51B indicate that CUSP/p73L, p40, and p51 are likely to be
splicing variants of the human homolog of rat KET (see Fig 5).
Figure 5. Diagram of the relationship of CUSP to p40, p51A, p51B,
and rat KET. Regions where the sequences are virtually identical are
depicted as identically filled boxes. The approximate locations of the
transactivation, DNA binding, and oligomerization domains are noted as
TA, DNA, and OLIG, respectively. Rat KET, the originally described
gene, is shown in the middle, with the human homologs of KET above
and below. Rat KET and p51B are virtually identical. CUSP/p73L and
p40 have a different 59 sequence than rat KET, with p40 having a truncated
39 region. CUSP/p73L have the same 39 sequence as rat KET and p51B.
p51A differs from p51B and rat KET at the 39 end.
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Figure 6. Expression of CUSP mRNA in cultured cells. Shown is a
northern blot hybridized to a CUSP probe in the upper panel (a) and to
an actin probe in the lower panel (b). The lanes contain RNA from the
following cultured cells: lane 1, A431 epithelial carcinoma cells; lane 2,
COS monkey kidney cells; lane 3, HaCaT transformed keratinocytes; lane
4, melanoma cells; and lane 5, normal human keratinocytes. The 4.7 kb
CUSP transcript (lower arrow) is readily identified in the keratinocyte-
derived cells. In lane 5, there is also a weak band at µ5.9 kb (upper arrow).
(CUSP and p73L are so nearly identical in sequence that they must
represent the same splicing variant; the minimal difference in
sequence can probably be attributed to sequencing artifact or to
sequence polymorphisms.) The likelihood that the human KET
homologs are splicing variants is rendered almost certain by the
localization of p40, p51, and p73L to the same area of chromosome
3 (Osada et al, 1998; Senoo et al, 1998; Trink et al, 1998).
Keratinocytes express at least one splicing variant of human KET,
but whether they express other splicing variants is not clear. When
we used the RACE technique to obtain the 59 sequence of CUSP,
three different reactions revealed the same sequence and did not
indicate 59 splicing variants. We have also failed to detect other
splice variants using the reverse transcriptase–polymerase chain
reaction with freshly obtained human epidermal sheets or cultured
human keratinocytes. Northern blotting of cultured keratinocytes
showed a strong band at 4.7 kb, which is consistent with the size
of CUSP, and a weak band of 5.8 kb. Transcripts of sizes previously
reported for other human KET variants were not detected. The
weak band of 5.8 kb may represent a polyadenylation variant of
CUSP, an unidentified splicing variant of human KET, or a
homologous gene hybridized to the probe. In any case, CUSP
appears to be the major transcript detected in keratinocytes.
As is the case with all the human KET variants, CUSP has a
greater similarity to p73 than to p53. CUSP has a 60% identity
with p73 throughout the coding region and a 94% identity with
p73 in the predicted amino acid sequence in four conserved regions
of the DNA-binding domain. Because p73 has greater similarity to
squid and to trout p53 than to human p53, it is speculated that
p73 and p53 diverged early in evolution, perhaps from an ancestral
p73-like gene (Kaghad et al, 1997) or KET-like gene.
Currently, the p53-like proteins have neither defined functions
nor defined roles in disease processes. This study provides a link,
albeit not completely elucidated, between a p53-like protein
and a disease process. Although it has not been established that
autoantibodies to CUSP cause the disease, the association of the
CUSP autoantigen with the CUS syndrome is clear. It is intriguing
that the CUS antigen is expressed in oral epithelium and skin, and
patients with CUS have lesions in oral epithelium and, occasionally,
skin. A direct pathogenic effect of anti-CUSP, however, has not
been addressed by these studies, and a possible mechanism of
pathogenesis is clearly open to speculation. It is notable that the
CUSP gene does not have an identifiable transactivation (I) domain
(Fig 4). The lack of a transactivation domain, together with highly
conserved sequence-specific DNA domains and oligomerization
domains, may mean that CUSP binds DNA but does not activate
genes. Theoretically, CUSP could compete with p53 or other
p53-like proteins for DNA binding sites, and could therefore
downregulate the effects of p53 or other p53-like proteins. If so,
as expression of p53, p73, and p51 has been shown to produce
apoptosis, CUSP may be in effect an anti-apoptotic protein. Should
autoantibody binding to CUSP alter its function, apoptotic epithelial
cell injury could conceivably result. The function of CUSP has yet
to be defined, however, and the link, if any, between anti-CUSP
and alteration of CUSP function has yet to be demonstrated.
In support of a relationship between autoantibodies to CUSP
and CUS is the apparent disease specificity of the autoantibodies.
Clearly, patients are classified as having CUS only if they have
antibodies to a nuclear epithelial antigen together with chronic
oral lesions, so a relationship between autoantibodies and disease
phenotype is implicit in the definition of CUS. Anti-CUSP
autoantibodies, however, are not commonly seen in other settings,
as confirmed by the lack of detection of anti-CUSP in 74
control sera. Anti-CUSP autoantibodies are not linked simply to
autoimmunity or to chronic oral lesions, as we did not find anti-
CUSP in sera from patients with other autoantibody specificities
(dermatomyositis and lupus patients) and in sera from patients with
other oral diseases (aphthous stomatitis and lichen planus). Our
studies do not, however, define exactly the specificity of anti-
CUSP for CUS, and we would not conclude that all individuals
with anti-CUSP must have or develop CUS.
It has not been established that the CUSP autoantigen is the
only autoantigen in CUS. Clearly, some patients’ autoantibodies
bind other proteins present in keratinocytes. The sequence similarity
between CUSP, p40, p51A, p51B, and even p73 and p53 could
result in cross-reactivities between CUSP and those proteins, and
such cross-reactivities could be of clinical significance. At the
present time, to our knowledge, only the p73 and p53 proteins
have been characterized in gel electrophoresis, and the proteins
encoded by the KET splicing variants, p40 and p51, have not been
characterized. The predicted amino acid sequences indicate though
that CUSP should have a somewhat different molecular weight
than the other p53-like proteins. The observation that the CUSP
band at 70 kDa in immunoblotting is the only band consistently
identified by all our patient sera indicates that it is likely to be the
major autoantigen. If other autoantigens are associated with CUS,
the frequent presence of a band at µ 52 kDa in immunoblotting
indicates that the µ52 kDa protein is the strongest candidate for
an additional autoantigen associated with CUS. We have affinity-
purified antibodies to 52 kDa protein from nitrocellulose and reacted
these antibodies in immunoblotting and immunofluorescence (data
not shown). The antibodies bind only the 52 kDa protein and not
70 kDa CUSP, and produce no staining of keratinocytes in
immunofluorescence. Also, antibodies affinity purified to 70 kDa
CUSP do not bind the 52 kDa protein in immunoblotting. The
identity of the 52 kDa protein has not been determined. Based on
the preceding results, however, it appears unlikely that the 52 kDa
protein is simply a degradation product of 70 kDa CUSP.
In summary, autoantibodies to the KET splicing variant, CUSP,
are associated with a distinctive clinical syndrome of chronic oral
ulceration. The p53-like genes, p73 and the several KET splicing
variants, are recently described genes of uncertain biologic and
pathologic significance (Kaelin, 1998). This study provides the clear
association of a p53-like protein with a disease process.
Note in proof. Recently, a gene called p63 has been reported
by Yaug et al. This gene is also the human homolog of KET.
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